The Impact of the COVID-19 Pandemic on Patient Disparities in Long-Term Opioid Therapy.

IF 2.4 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Sebastian T Tong, Zihan Zheng, Maria G Prado, Imara I West, Joseph W LeMaster, Mary A Hatch, Lili S Szabo, Tracy M Anastas, Kris Pui Kwan Ma, Kari A Stephens
{"title":"The Impact of the COVID-19 Pandemic on Patient Disparities in Long-Term Opioid Therapy.","authors":"Sebastian T Tong, Zihan Zheng, Maria G Prado, Imara I West, Joseph W LeMaster, Mary A Hatch, Lili S Szabo, Tracy M Anastas, Kris Pui Kwan Ma, Kari A Stephens","doi":"10.3122/jabfm.2023.230359R1","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The COVID-19 pandemic disrupted how primary care patients with chronic pain received care. Our study sought to understand how long-term opioid therapy (LtOT) for chronic pain changed over the course of the pandemic overall and for different demographic subgroups.</p><p><strong>Methods: </strong>We used data from electronic health records of 64 primary care clinics across Washington state and Idaho to identify patients who had a chronic pain diagnosis and were receiving long-term opioid therapy. We defined 10-month periods in 2019 to 2021 as prepandemic, early pandemic and late pandemic and used generalized estimating equations analysis to compare across these time periods and demographic characteristics.</p><p><strong>Results: </strong>We found a proportional decrease in LtOT for chronic pain in the early months of the pandemic (OR = 0.94, <i>P = .007</i>) followed by an increase late pandemic (OR = 1.08, <i>P = .002</i>). Comparing late pandemic to prepandemic, identifying as Asian or Black, having fewer comorbidities, or living in an urban area were associated with higher likelihood of being prescribed LtOT.</p><p><strong>Discussion: </strong>The use of LtOT for chronic pain in primary care has increased from before to after the COVID-19 pandemic with racial/ethnic and geographic disparities. Future research is needed to understand these disparities in LtOT and their effect on patient outcomes.</p>","PeriodicalId":50018,"journal":{"name":"Journal of the American Board of Family Medicine","volume":"37 2","pages":"290-294"},"PeriodicalIF":2.4000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the American Board of Family Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3122/jabfm.2023.230359R1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The COVID-19 pandemic disrupted how primary care patients with chronic pain received care. Our study sought to understand how long-term opioid therapy (LtOT) for chronic pain changed over the course of the pandemic overall and for different demographic subgroups.

Methods: We used data from electronic health records of 64 primary care clinics across Washington state and Idaho to identify patients who had a chronic pain diagnosis and were receiving long-term opioid therapy. We defined 10-month periods in 2019 to 2021 as prepandemic, early pandemic and late pandemic and used generalized estimating equations analysis to compare across these time periods and demographic characteristics.

Results: We found a proportional decrease in LtOT for chronic pain in the early months of the pandemic (OR = 0.94, P = .007) followed by an increase late pandemic (OR = 1.08, P = .002). Comparing late pandemic to prepandemic, identifying as Asian or Black, having fewer comorbidities, or living in an urban area were associated with higher likelihood of being prescribed LtOT.

Discussion: The use of LtOT for chronic pain in primary care has increased from before to after the COVID-19 pandemic with racial/ethnic and geographic disparities. Future research is needed to understand these disparities in LtOT and their effect on patient outcomes.

COVID-19 大流行对阿片类药物长期治疗患者差异的影响。
背景:COVID-19大流行扰乱了慢性疼痛初级保健患者接受治疗的方式。我们的研究旨在了解慢性疼痛的长期阿片类药物治疗(LtOT)在整个大流行期间以及不同人口亚群中的变化情况:我们使用了华盛顿州和爱达荷州 64 家初级保健诊所的电子健康记录数据,以确定诊断为慢性疼痛并正在接受长期阿片类药物治疗的患者。我们将 2019 年至 2021 年的 10 个月期间定义为大流行前、大流行早期和大流行晚期,并使用广义估计方程分析法对这些时间段和人口特征进行比较:我们发现,在大流行初期,慢性疼痛患者的 LtOT 比例下降(OR = 0.94,P = .007),而在大流行后期则有所上升(OR = 1.08,P = .002)。大流行后期与大流行前期相比,亚裔或黑人身份、较少合并症或居住在城市地区与被开具LtOT处方的可能性较高有关:讨论:从 COVID-19 大流行之前到之后,基层医疗机构使用 LtOT 治疗慢性疼痛的情况有所增加,但存在种族/族裔和地域差异。未来的研究需要了解 LtOT 的这些差异及其对患者预后的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.90
自引率
6.90%
发文量
168
审稿时长
4-8 weeks
期刊介绍: Published since 1988, the Journal of the American Board of Family Medicine ( JABFM ) is the official peer-reviewed journal of the American Board of Family Medicine (ABFM). Believing that the public and scientific communities are best served by open access to information, JABFM makes its articles available free of charge and without registration at www.jabfm.org. JABFM is indexed by Medline, Index Medicus, and other services.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信